Philippe Pouletty, a French trained medical doctor and general partner at Paris-based Truffle Capital has reason to look especially cheerful these days. Carmat, a company building an entirely artificial human heart, is planning an initial public offering in June - the  third company in Pouletty's portfolio to go public in as many months. Though no one expects 2010 to look like 1999 the market for IPOs - particularly in biotech - appears to be open once again.Read more

France's Carmat, a company that is building an entirely artificial human heart, is planning an initial public offering on the Alternext market of NYSE-Euronext Paris in June. The company, co-founded by renowned French heart surgeon Alain Carpentier, is leveraging the aerospace industry's expertise in modeling, stress testing, miniaturization and design for severe environments as well as the latest advances in software, medicine, biology and materials science. Click to read the story and see the video. Read more